Core Insights - The company reported its latest research findings on two new targeted therapies for lung cancer at the 2025 World Lung Cancer Conference (WCLC) [1] Group 1: Company Developments - The company presented 11 recent studies on its self-developed lung cancer targeted drug, Shuwotai (generic name: Shuwotai tablets), and the highly selective JAK1 inhibitor, Gaoruizhe (generic name: Golixitinib capsules) in the non-small cell lung cancer (NSCLC) field [1] - The international multicenter registration clinical study "Wukong 1B" (WU-KONG1B) of Shuwotai had its latest research results reported orally at the conference [1]

Core Viewpoint - DIZHE Pharmaceutical (688192.SH) reported promising results for its self-developed lung cancer targeted drug, Shuwozhe®, and high-selectivity JAK1 inhibitor, Gaoruizhe®, at the 2025 World Lung Cancer Conference (WCLC) [1] Group 1: Clinical Research Findings - The latest results from the international multicenter registration clinical study "WUKONG1B" for Shuwozhe® were presented at the conference [1] - Shuwozhe® demonstrated a favorable benefit/risk ratio in the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations [1] - The overall response rate (ORR) for Shuwozhe® combined with Anlotinib in first-line treatment of EGFR-sensitive mutations with co-mutations in NSCLC was reported at 77.8%, with a disease control rate (DCR) of 100% [1]

证券日报网讯 9月5日晚间，迪哲医药发布公告称，公司计划于2025年9月16日（星期二）15：00-17： 00参加2025年半年度科创板创新药行业集体业绩说明会。 （文章来源：证券日报） ...

Core Viewpoint - The company, Dizalpharma, is set to hold a collective performance briefing for the first half of 2025 on September 16, 2025, to discuss its operational results and financial status with investors [1][2]. Group 1: Meeting Details - The meeting will take place on September 16, 2025, from 15:00 to 17:00 [1][2]. - It will be held at the Shanghai Stock Exchange Roadshow Center, accessible via the website [1][2]. - The format of the meeting will be an interactive online session [2]. Group 2: Participation Information - Investors can submit questions from September 9, 2025, to September 15, 2025, via the Roadshow Center website or through the company's email [3]. - The company will address commonly asked questions during the briefing [3]. Group 3: Participants - Key participants include the Chairman and General Manager, Dr. Zhang Xiaolin, and the Secretary of the Board and CFO, Mr. Lv Hongbin, along with independent directors [2]. Group 4: Contact Information - For inquiries, investors can contact the Board Office via phone or email [3].

华泰联合证券有限责任公司 关于迪哲（江苏）医药股份有限公司 2025 年半年度持续督导跟踪报告 | 保荐机构名称：华泰联合证券有限责任 | 被保荐公司简称：迪哲（江苏）医药股份有限公 | | --- | --- | | 公司 | 司 | | 保荐代表人姓名：许超 | 联系电话：010- 56839300 | | 保荐代表人姓名：丁明明 | 联系电话：010- 56839300 | 华泰联合证券有限责任公司（以下简称"华泰联合证券"、"保荐机构"） 作为迪哲（江苏）医药股份有限公司（以下简称"迪哲医药"或"公司"）2023 年度向特定对象发行 A 股股票的保荐机构，根据《证券法》《证券发行上市保荐 业务管理办法》和《上海证券交易所科创板股票上市规则》等有关法律、法规的 规定履行公司 2023 年度向特定对象发行 A 股股票的持续督导职责，对迪哲医药 进行持续督导，并出具本持续督导跟踪报告： 一、保荐机构和保荐代表人发现的问题及整改情况 无。 二、重大风险事项 （一）尚未盈利的风险 创新药研发周期长、资金投入大、盈利周期长。作为一家致力于创新的全球 性生物医药企业，公司目前有七款创新药物处于全球临床研发阶段。其中 ...

证券代码：688192 证券简称：迪哲医药 公告编号：2025-52 迪哲（江苏）医药股份有限公司 关于参加 2025 年半年度科创板创新药行业 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） ● 会议召开方式：上证路演中心网络互动 ● 投资者可于 2025 年 9 月 9 日（星期二）至 9 月 15 日（星期一） 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过 公司邮箱 IR@dizalpharma.com 进行提问。公司将在说明会上对投资 者普遍关注的问题进行回答。 迪哲（江苏）医药股份有限公司（以下简称"公司"）已于 2025 年 8 月 23 日发布公司 2025 年半年度报告，为便于广大投资者更全面 深入地了解公司 2025 年半年度经营成果、财务状况，公司计划于 2025 年 9 月 16 日（星期二）15:00-17:00 参加 2025 年半年度科创板创新药 行业集体业绩说明会，就投资者关心 ...

Core Viewpoints - The company reported a significant increase in revenue and a reduction in net loss, indicating strong commercial growth driven by its dual product strategy in the healthcare sector [1] - The global Phase III trial for Shuwotini has completed enrollment, with ongoing expansion into resistant NSCLC and other indications, showcasing its clinical value [2] - The efficacy of Gaurizhe has been recognized with top-level recommendations, and the company is exploring its combination with PD-1 for resistant NSCLC, indicating potential in solid tumor applications [3] Financial Performance - In the first half of the year, the company achieved a revenue of 355 million yuan, representing a 74% increase, while net loss narrowed to 379 million yuan [1] - The sales expense ratio decreased by 24 percentage points to 76%, and cash and cash equivalents increased by 172% to 2.251 billion yuan [1] Pipeline Development - The company has a diverse pipeline with multiple innovative products, including Birelentinib, which has shown significant anti-tumor activity and received FDA fast track designation [4] - DZD6008 is positioned as a fourth-generation EGFR TKI targeting resistant mutations, with registration clinical trials expected to start in 2026 [4] - GW5282 demonstrates potential in both hematological and solid tumors, validating the company's diversified innovation strategy [4] Revenue Forecast and Investment Recommendations - The company is projected to achieve revenues of 860 million, 1.47 billion, and 2.2 billion yuan in 2025, 2026, and 2027, respectively, with year-on-year growth rates of 138.6%, 71.0%, and 49.9% [5] - The company is expected to remain in a loss position in 2025 and 2026, with net profits projected to turn positive in 2027 [5] - The dual product strategy and ongoing clinical developments support a "buy" rating based on the FCFF valuation method [5]

Core Insights - The food and beverage industry maintains the highest gross margin at 51.41% in the first half of the year, excluding the financial sector [1] - The beauty and personal care, as well as the media industries, rank second and third in gross margin [1] - The pharmaceutical and computer sectors dominate individual stock performance, with the top five companies by gross margin being Hai Chuang Pharmaceutical-U, Ailis, Dameng Data, Dize Pharmaceutical-U, and Zhongwang Software [1] - Hai Chuang Pharmaceutical-U leads with an impressive gross margin of 99.52%, while 27 companies reported gross margins exceeding 90% in the first half of the year [1]

Core Viewpoint - Dize Pharmaceutical experienced a decline of 4.31% in stock price on August 27, with a trading volume of 423 million yuan, indicating potential market volatility and investor sentiment concerns [1] Financing Summary - On August 27, Dize Pharmaceutical had a financing buy-in amount of 23.54 million yuan and a financing repayment of 35.11 million yuan, resulting in a net financing outflow of 11.57 million yuan [1] - The total financing and securities lending balance for Dize Pharmaceutical reached 151 million yuan, with the financing balance accounting for 0.48% of the circulating market value, indicating a high level compared to the past year [1] - The company had a securities lending repayment of 400 shares and a securities lending sell-out of 200 shares, with a sell-out amount of 15,100 yuan, and a securities lending balance of 1.13 million yuan, also reflecting a high level compared to the past year [1] Company Profile - Dize Pharmaceutical, established on October 27, 2017, and listed on December 10, 2021, is located in Wuxi, Jiangsu Province, focusing on the research and industrialization of innovative drugs, with 100% of its main business revenue derived from drug sales [1] Financial Performance - As of June 30, 2025, Dize Pharmaceutical reported a revenue of 355 million yuan, representing a year-on-year growth of 74.40%, while the net profit attributable to the parent company was -37.7 million yuan, a decrease of 9.46% year-on-year [2] - The number of shareholders decreased by 3.45% to 8,386, while the average circulating shares per person increased by 3.58% to 22,265 shares [2] Institutional Holdings - As of June 30, 2025, the top ten circulating shareholders included new entrants such as Yongying Pharmaceutical Innovation Mixed Fund A and Zhongou Medical Health Mixed Fund A, while some existing shareholders like Ping An Medical Health Mixed Fund A exited the top ten list [2]

Core Viewpoint - Dize Pharmaceutical (688192.SH) reported a significant increase in revenue for the first half of 2025, but continued to incur net losses, indicating ongoing financial challenges despite growth in sales [1][2]. Financial Performance - For the first half of 2025, the company achieved operating revenue of 355 million CNY, representing a year-on-year increase of 74.40% [1][2]. - The net profit attributable to shareholders was -377 million CNY, compared to -344 million CNY in the same period last year [1][2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -419 million CNY, up from -380 million CNY year-on-year [1][2]. - The net cash flow from operating activities was -265 million CNY, an improvement from -301 million CNY in the previous year [1][2]. Historical Financial Data - The company has shown fluctuating revenue and increasing net losses from 2019 to 2024, with revenues of 4.10 million CNY in 2019, dropping to 3.60 billion CNY in 2024, while net losses grew from -446 million CNY in 2019 to -846 million CNY in 2024 [5][8]. - The operating cash flow has also been negative throughout the years, indicating ongoing liquidity challenges [5][8]. Fundraising Activities - Dize Pharmaceutical raised a total of 3.899 billion CNY through two rounds of fundraising, with the first round raising 2.103 billion CNY and the second round raising approximately 1.795 billion CNY [3][4]. - The funds raised are intended for new drug research and development as well as to supplement working capital [3].